Company news

Septerna, Inc. news in 2025

Septerna, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference

December 16, 2025

Septerna to Participate in 8th Annual Evercore Healthcare Conference

November 24, 2025

Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results

November 9, 2025

Septerna to Participate in Upcoming Investor Conferences

November 2, 2025

Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors

September 28, 2025

Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases

August 20, 2025

Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results

August 10, 2025

Septerna to Present at Jefferies Global Healthcare Conference

May 28, 2025

Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results

May 14, 2025

Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results

March 26, 2025

Septerna to Present at TD Cowen 45th Annual Health Care Conference

February 25, 2025

Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist

February 17, 2025

Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer

January 5, 2025

Decks in 2025